Research Projects of SFB1399

Our consortium is highly interdisciplinary, covering expertise in biochemistry and signaling, structural biology, medicinal chemistry and structure-guided drug design, cancer immunology and inflammation, mouse models, cancer genomics, computational genomics, molecular pathology, as well as clinical trials.

Research Area A

Targeting oncogenic transformation in SCLC

A01

Identification and characterization of molecular vulnerabilities in SCLC

Christian Reinhardt | Filippo Beleggia

A02

MYC gene family members as modulators of tumorigenesis and druggable signaling pathways in SCLC – terminated

Martin Sos

A03

Targeting telomere maintenance mechanisms in SCLC

Matthias Fischer

A04

Inflammatory and necroptotic signaling in SCLC

Manolis Pasparakis

A05

Immuno-editing via programmed cell death in SCLC

Silvia von Karstedt

A06

CDK9 inhibition for the treatment of drug resistance in SCLC – terminated

M. Nieves Peltzer

A07

Targeting key drivers in SCLC for the development of new therapeutic concepts

Stefan Knapp

A08

Targeted exploitation of inflammatory programs in SCLC

Martin Lukas Sos

A09

Mechanism of resistance in SCLC defined by pyroptotic-to-apoptotic switch

M. Nieves Peltzer

Research Area B

Genetic and epigenetic determinants of drug sensitivity and resistance in SCLC

B01

Mechanisms of drug sensitivity and resistance in SCLC

Roman K. Thomas | Julie George

B02

Clonal evolution of SCLC

Martin Pfeifer

B03

Mutations in epigenetic modifiers and their impact on tumorigenesis and drug response in SCLC – terminated

Michal R. Schweiger

B04

Chemical biology analysis of epigenetics in SCLC – terminated

Stefan Knapp

B05

Decoding epigenetic subtypes, resistance mechanisms and vulnerabilities of small cell lung cancer

Robert Hänsel-Hertsch

B06

The relevance of helicase activity for genome stability changes within small cell lung cancer

Katrin Paeschke

B07

Characterization of metabolic reprogramming in Small Cell Lung Cancer subtype plasticity and progression

Christian Frezza

B08

Metabolic characterization of innate lymphoid cells in small cell lung cancer

Laura Surace

B09

SCLC response to chemotherapy and ionizing γ-radiation

Maria Cartolano

Research Area C

Targeting the immune response in SCLC

C01

Molecular characterization of the immunogenic profile in SCLC tumors

Julie George

C02

Harnessing molecular vulnerabilities to promote an antitumor immune microenvironment – terminated

Grit S. Herter-Sprie | H. Christian Reinhardt

C03

Immuno-peptidomics of SCLC

Hans-Georg Rammensee | Cécile Gouttefangeas

C04

Modulating immune pathways in SCLC cells

Michael Hölzel

C05

T cell recognition and immune editing in SCLC

Ugur Sahin | Laura Kolb

C06

Understanding and therapeutically harnessing the tumor-supportive and immuno-suppressive functions of TRAIL and CD95L in SCLC

Henning Walczak | Gianmaria Liccardi

C07

Exploiting innate nucleic acid receptor pathways to enhance immunotherapy in SCLC

Johannes Brägelmann

Research Area Z

Central Projects

Z01

A translational and computational platform for longitudinal studies of SCLC under therapy

Jürgen Wolf | Katja Höpker

Z03

In vivo imaging of tumors

Holger Grüll

Z04

Translational pathology core

Alexander Quaas | Anne M. Schultheis | Udo Siebolts

INF

INF, Bioinformatics, Research-Data Management, IT Infrastructure and Optimization

Jasmin Schenk | Stefan Wesner | Martin Peifer

Z05

Central Tasks of the Collaborative Research Center

Roman K. Thomas